--- Here are the main takeaways: -All three drugs evaluated (injectable semaglutide, oral semaglutide, and tirzepatide) produced significant weight loss and improved metabolic risk factors in people without diabetes
Fasting is optional , but particularly helpful in CSP where fewer glucose peaks mean better VAT control
Upon activation by its endogenous ligand, GIP, the receptor stimulates insulin secretion from pancreatic -cells in a glucose-dependent manner, while also exerting pleiotropic effects on adipose tissue, bone metabolism, and the central nervous system [2, 3]
Other contributing factors include chronic inflammation , hormonal imbalances (such as polycystic ovary syndrome), certain medications (including corticosteroids), and ageing
00:04:26 Sara Klockars And then we have the rare risks, such as pancreatitis or gallbladder disease, that can present severe abdominal pain
Here's how the dual mechanism works: Appetite control: Tirzepatide mimics GLP-1 and GIP, gut hormones that signal fullness to the brain
